BEDFORD, Mass. — August 5, 2025 — Leads & Copy — Ocular Therapeutix, Inc. reported its Q2 2025 financial results and provided a business update, highlighting progress in its AXPAXLI™ SOL trials for wet AMD. SOL-1 remains on track for Q1 2026 topline data, while SOL-R’s rescue criteria have been streamlined, with topline data expected in 1H 2027. The company plans a single long-term extension study for both SOL trials.
Ocular Therapeutix will host an Investor Day on September 30, 2025, in New York City. The company raised approximately $97 million in June 2025 through its existing ATM facility and reported a cash balance of $391.1 million as of June 30, 2025, with an expected runway into 2028.
According to Pravin U. Dugel, MD, Executive Chairman, President and Chief Executive Officer of Ocular Therapeutix, the company is entering a crucial phase, building a differentiated clinical profile for AXPAXLI, and potentially securing a superiority label in wet AMD. Ocular is also advancing its NPDR and DME program, with more details to be shared at the Investor Day in September. The company’s new branding reflects its focus on retina and commitment to patient-driven solutions.
Recent achievements include outstanding patient retention and protocol adherence in the SOL-1 trial, along with streamlined rescue criteria in the SOL-R trial. The company plans to file an NDA for FDA review shortly after topline results in SOL-R, leveraging the 505(b)(2) pathway to potentially shorten the review timeline. Written feedback has been received from the FDA on the registrational trial in non-proliferative diabetic retinopathy (NPDR) for AXPAXLI.
Q2 2025 financial results show total net revenue of $13.5 million, an 18.1% decrease compared to $16.4 million in Q2 2024. Research and development expenses were $51.1 million, while selling and marketing expenses were $13.7 million. The net loss for the quarter was $(67.8) million, or $(0.39) per share. Outstanding shares as of August 1, 2025, were approximately 174.0 million.
Contact:
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
Source: Ocular Therapeutix, Inc.
